Optimizerx Corporation (OPRX)

Market Closed

16 Oct, 08:00 PM

NASDAQ (CM)

8. 50

-0.35

-3.9548%

155.37M Market Cap

- P/E Ratio

- Div Yield

101,176 Volume

0.38 Eps

$ 8.85

Previous Close

Investors:

Add Transaction

Day Range

8.49 8.99

Year Range

4.54 22.25

Want to track OPRX and more in your Portfolio? 🎯

Get Started For Free

OptimizeRx: Gross Margin Gains And Improved Long-Term Outlook

OptimizeRx is upgraded to 'Buy' due to an improved 2027 growth outlook and an attractive valuation. Q2 2026 saw gross margin rise to 76.5%, marking five consecutive quarters of gains amid a strategic shift to higher-margin offerings. OPRX reaffirmed 2026 guidance: revenue of $95M–$100M and adjusted EBITDA of $21M–$25M.

Seekingalpha | 4 weeks ago

OptimizeRx Q2 Earnings Call Highlights

OptimizeRx NASDAQ: OPRX reported second-quarter fiscal 2026 revenue of $20.5 million, down 30% from $29.2 million a year earlier, while adjusted EBITDA totaled $4.9 million, management said on its earnings call. The company reaffirmed its full-year revenue outlook of $95 million to $100 million and adjusted EBITDA guidance of $21 million to $25 million.

Marketbeat | 2 months ago

OptimizeRx Corporation (OPRX) Q2 2026 Earnings Call Transcript

Seekingalpha | 2 months ago

OptimizeRx Corp. (OPRX) Q2 Earnings and Revenues Top Estimates

OptimizeRx Corp. (OPRX) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.24 per share a year ago.

Zacks | 2 months ago

OptimizeRx vs. Doximity: Which Digital Health Stock Is the Better Bet?

OPRX and DOCS are betting big on AI-driven healthcare engagement as cautious pharma spending pressures near-term growth.

Zacks | 4 months ago

OptimizeRx Stock Down 30% in a Month: Should Investors Hold or Fold?

OPRX's shares slid 30% in a month as MFN pricing and cautious pharma spending hit revenue, even as DAAP growth and EBITDA surged.

Zacks | 4 months ago

OPRX Boosts DSP Revenue Potential While Navigating Near-Term Headwinds

OptimizeRx expands DSP integration to unlock scalable EHR ad campaigns and boost inventory use despite lowering 2026 revenue guidance.

Zacks | 4 months ago

OptimizeRx Cuts Revenue Outlook: Will Pressures Ease Ahead?

OptimizeRx Corporation OPRX trimmed its 2026 revenue outlook, reflecting ongoing near-term pressures. Revenues are now expected to be between $95 million and $100 million, compared with the previous range of $109-$114 million.

Zacks | 5 months ago

OptimizeRx Q1 Earnings Call Highlights

OptimizeRx NASDAQ: OPRX reported first-quarter fiscal 2026 results that topped consensus expectations, while management lowered its full-year revenue outlook, citing continued caution among life sciences customers and shorter contract commitments tied in part to most-favored-nation pricing dynamics and other macroeconomic pressures.

Marketbeat | 5 months ago